Objective and self-reported evidence of dextromethorphan antitussive efficacy in children, aged 6–11 years, with acute cough due to the common cold

This multiple‐dose, double‐blind, placebo‐controlled, randomized trial was undertaken to establish the most suitable objective and subjective endpoints for evaluating the anti-tussive efficacy of dextromethorphan hydrobromide; the study included 128 children aged 6–11 years with cough due to the common cold. The primary endpoint was total cough count in the first 24 hours following treatment. Secondary endpoints included hourly day time and night-time cough counts, cough rates during each morning and afternoon dosing interval, and total time per 24 hours in which cough events occurred. Cough was objectively measured using the Vitalograph VitaloJAK cough counting monitor.